SQ109 analogues as potential antimicrobial candidates

被引:0
|
作者
Oluseye K. Onajole
Xoliswa V. Belewa
Yacoob Coovadia
Thavendran Govender
Hendrik G. Kruger
Glenn E. M. Maguire
Dianithi Naidu
Benesh Somai
Nisha Singh
Patrick Govender
机构
[1] University of KwaZulu-Natal,School of Chemistry
[2] Nelson Mandela Metropolitan University,Department of Biochemistry and Microbiology
[3] National Health Laboratory Services (NHLS),Microbiology
[4] Inkosi Albert Luthuli Central Hospital,School of Pharmacy and Pharmacology
[5] University of KwaZulu-Natal,School of Biological and Conservation Sciences
[6] University of KwaZulu-Natal,School of Biochemistry, Genetics and Microbiology
[7] University of KwaZulu-Natal,undefined
来源
关键词
Antimicrobial activity; Structural activity relationship; 1,2-Diamine;
D O I
暂无
中图分类号
学科分类号
摘要
The antimicrobial activity of five novel SQ109 derivatives including SQ109 against bacteria, yeast and filamentous fungi is reported herein. Using broth microdilution techniques, compounds 2 and 3 were found to be active against most tested fungi and bacteria, with minimum inhibitory concentrations (MICs) ranging from 0.98 to 31 μg ml−1, except for Klebsiella pneumonia where the MIC was 250 μg ml−1. SQ109 and derivative 4 did not show any significant activity against most of the organisms used. However, their reduced derivatives 1 and 5 showed promising activity with MICs between 0.49 and 62.5 μg ml−1 against most of the microorganisms used.
引用
收藏
页码:1394 / 1401
页数:7
相关论文
共 50 条
  • [31] Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines
    Protopopova, M
    Hanrahan, C
    Nikonenko, B
    Samala, R
    Chen, P
    Gearhart, J
    Einck, L
    Nacy, CA
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (05) : 968 - 974
  • [32] SQ109 inhibits proliferation of Leishmania donovani by disruption of intracellular Ca2+ homeostasis, collapsing the mitochondrial electrochemical potential (ΔΨm) and affecting acidocalcisomes
    Zain Gil
    Nathalia Martinez-Sotillo
    Andrea Pinto-Martinez
    Fabiola Mejias
    Juan Carlos Martinez
    Ivan Galindo
    Eric Oldfield
    Gustavo Benaim
    [J]. Parasitology Research, 2020, 119 : 649 - 657
  • [33] Drug therapy of experimental tuberculosis (TB): Improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs
    Nikonenko, Boris V.
    Protopopova, Marina
    Sarnala, Rowena
    Einck, Leo
    Nacy, Carol A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (04) : 1563 - 1565
  • [34] Inhibition Mechanism of Anti-TB Drug SQ109: Allosteric Inhibition of TMM Translocation of Mycobacterium Tuberculosis MmpL3 Transporter
    Carbone, Justin
    Paradis, Nicholas J.
    Bennet, Lucas
    Alesiani, Mark C.
    Hausman, Katherine R.
    Wu, Chun
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2023, 63 (16) : 5356 - 5374
  • [35] Analysis of the oligomeric state of mycobacterial membrane protein large 3 and its interaction with SQ109 with native cell membrane nanoparticles system
    Qiu, Weihua
    Guo, Youzhong
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2022, 1864 (01):
  • [36] MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature
    Imran, Mohd.
    Arora, Mandeep Kumar
    Chaudhary, Anurag
    Khan, Shah Alam
    Kamal, Mehnaz
    Alshammari, Manal Mutlaq
    Alharbi, Raghad Mohammad
    Althomali, Nuha Abdullah
    Alzimam, Ibrahim Mohammed
    Alshammari, Abdullah Ayed
    Alharbi, Bashair Hamed
    Alshengeti, Amer
    Alsaleh, Abdulmonem A.
    Alqahtani, Shayea A.
    Rabaan, Ali A.
    [J]. BIOMEDICINES, 2022, 10 (11)
  • [37] 抗结核新药SQ109、PA-824、OPC-67683与R207910研究进展
    谭金哲
    董景涛
    [J]. 中国抗生素杂志, 2010, 35 (06) : 408 - 413
  • [38] Study of SQ109 analogs binding to mycobacterium MmpL3 transporter using MD simulations and alchemical relative binding free energy calculations
    Marianna Stampolaki
    Ioannis Stylianakis
    Helen I. Zgurskaya
    Antonios Kolocouris
    [J]. Journal of Computer-Aided Molecular Design, 2023, 37 : 245 - 264
  • [39] High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
    Boeree, Martin J.
    Heinrich, Norbert
    Aarnoutse, Rob
    Diacon, Andreas H.
    Dawson, Rodney
    Rehal, Sunita
    Kibiki, Gibson S.
    Churchyard, Gavin
    Sanne, Ian
    Ntinginya, Nyanda E.
    Minja, Lilian T.
    Hunt, Robert D.
    Charalambous, Salome
    Hanekom, Madeleine
    Semvua, Hadija H.
    Mpagama, Stellah G.
    Manyama, Christina
    Mtafya, Bariki
    Reither, Klaus
    Wallis, Robert S.
    Venter, Amour
    Narunsky, Kim
    Mekota, Anka
    Henne, Sonja
    Colbers, Angela
    van Balen, Georgette Plemper
    Gillespie, Stephen H.
    Phillips, Patrick P. J.
    Hoelscher, Michael
    [J]. LANCET INFECTIOUS DISEASES, 2017, 17 (01): : 39 - 49
  • [40] SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis
    Tahlan, Kapil
    Wilson, Regina
    Kastrinsky, David B.
    Arora, Kriti
    Nair, Vinod
    Fischer, Elizabeth
    Barnes, S. Whitney
    Walker, John R.
    Alland, David
    Barry, Clifton E., III
    Boshoff, Helena I.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (04) : 1797 - 1809